vimarsana.com

Latest Breaking News On - Syros pharmaceuticals stock performance - Page 1 : vimarsana.com

Avidity Partners Management LP Has $13 04 Million Stock Holdings in Syros Pharmaceuticals, Inc (NASDAQ:SYRS)

Avidity Partners Management LP increased its position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Free Report) by 5.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,673,538 shares of the company’s stock after purchasing an additional 92,396 shares during the […]

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […]

Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews com

StockNews.com lowered shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) from a hold rating to a sell rating in a research report released on Friday. Several other research firms also recently commented on SYRS. Piper Sandler reaffirmed an overweight rating and set a $13.00 price objective on shares of Syros Pharmaceuticals in a report on […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.